BANK VONTOBEL/CALL/GILEAD SCIENCES/76/0.05/21.06.24

BANK VONTOBEL/CALL/GILEAD SCIENCES/76/0.05/21.06.24 Stock

Warrant

WGIARV

CH1260793489

Market Closed - Bid/Ask 11:20:00 2024-05-03 am EDT			After market 11:15:01 am
0.02 ^CHF	-4.76%		0.011	-45.00%

3 months	-92.16%
6 months	-96.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BANK VONTOBEL/CALL/GILEAD SCIENCES/76/0.05/21.06.24

Latest news about GILEAD SCIENCES, INC.

New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit from Earlier Lines of Treatment	11:15am	AQ
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	Jun. 14	DJ
EU regulator mandates label updates on CAR-T cancer therapies	Jun. 14	RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta	Jun. 14	MT

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Vontobel
	WGIARV
ISIN	CH1260793489
Date issued	2023-05-26
Strike	76 $
Maturity	2024-06-21 (4 Days)
Parity	20 : 1
Emission price	0.46 CHF
Emission volume	N/A
Settlement	Physisch
Currency	CHF

Technical Indicators

Highest since issue	0.59 CHF
Lowest since issue	0.02 CHF
Spread	0.018 CHF
Spread %	90.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company